Adaptimmune Therapeutics Plc has returned to Nasdaq to raise new capital with an underwritten public offering of 24 million American depositary shares (ADSs) at a price of $4 per ADS. The issue raised a net $89.8 million after underwriters exercised their option to purchase additional shares. The company will use the proceeds to advance the development of its portfolio of immunotherapies for cancer which it is doing independently and through partnerships.
